PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34926239-0 2021 DPP4 Regulates DHCR24-Mediated Cholesterol Biosynthesis to Promote Methotrexate Resistance in Gestational Trophoblastic Neoplastic Cells. Cholesterol 31-42 dipeptidyl peptidase 4 Homo sapiens 0-4 11773049-5 2002 The sorting mechanism of DPPIV implicates its association with detergent-insoluble membrane microdomains containing cholesterol and sphingolipids, whereas an efficient association largely depends on the presence of a fully complex N- and O-linked glycosylated DPPIV. Cholesterol 116-127 dipeptidyl peptidase 4 Homo sapiens 25-30 11773049-6 2002 Interestingly, cholesterol is a more critical component in this context than sphingolipids, because cholesterol depletion by beta-cyclodextrin affects the detergent solubility and the sorting behavior of DPPIV more strongly than fumonisin, an inhibitor of sphingolipid synthesis. Cholesterol 15-26 dipeptidyl peptidase 4 Homo sapiens 204-209 11773049-6 2002 Interestingly, cholesterol is a more critical component in this context than sphingolipids, because cholesterol depletion by beta-cyclodextrin affects the detergent solubility and the sorting behavior of DPPIV more strongly than fumonisin, an inhibitor of sphingolipid synthesis. Cholesterol 100-111 dipeptidyl peptidase 4 Homo sapiens 204-209 34926239-11 2021 In conclusion, our findings suggested that DPP4 might regulate DHCR24-mediated cholesterol biosynthesis to promote methotrexate resistance in GTN cells. Cholesterol 79-90 dipeptidyl peptidase 4 Homo sapiens 43-47 23994650-4 2013 The peak sCD26/DPP4 level correlated positively with the baseline age and body mass index, and fasting plasma glucose (FPG), homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides (TG), alanine aminotransferase, and gamma-glutamyl transpeptidase (GGT) levels whereas it correlated negatively with high-density lipoprotein (HDL) cholesterol and the serum levels of total and high-molecular weight (HMW) adiponectin. Cholesterol 349-360 dipeptidyl peptidase 4 Homo sapiens 15-19 34333803-8 2021 DPP-4 inhibitors and metformin showed favorable effects on improving metabolic syndrome by decreasing blood pressure, serum triglycerides (TG), low-density lipoprotein (LDL), total cholesterol, and increasing high-density lipoprotein (HDL), plus their positive impacts on weight. Cholesterol 181-192 dipeptidyl peptidase 4 Homo sapiens 0-5 34926239-4 2021 Cholesterol biosynthesis-related metabolites were markedly impacted by DPP4 knockdown in MTX-resistant sublines. Cholesterol 0-11 dipeptidyl peptidase 4 Homo sapiens 71-75 34926239-5 2021 Manipulation of DPP4 expression remarkably affected the level of cellular cholesterol in GTN cells. Cholesterol 74-85 dipeptidyl peptidase 4 Homo sapiens 16-20 34926239-10 2021 Further, DPP4 inhibitor sitagliptin effectively inhibited cholesterol biosynthesis, reduced DHCR24 expression and enhanced MTX-induced cytotoxicity in vitro and in vivo. Cholesterol 58-69 dipeptidyl peptidase 4 Homo sapiens 9-13 32422444-9 2020 Patients with T1DM were classified into 3 groups according to DPP-4 tertiles showing significant increase in BMI SDS and total cholesterol across the 3 groups. Cholesterol 127-138 dipeptidyl peptidase 4 Homo sapiens 62-67 33538983-7 2021 The decrease in DPP4 activity was significantly correlated with decreases in BMI, improved cholesterol levels, reduced hepatic injury markers as well as improved post-prandial insulin sensitivity. Cholesterol 91-102 dipeptidyl peptidase 4 Homo sapiens 16-20 33538983-10 2021 The associations between decreased DPP4 activity and improved cholesterol levels as well as hepatic injury markers point towards pleiotropic effects of DPP4 beyond glucose metabolism which warrant further investigation. Cholesterol 62-73 dipeptidyl peptidase 4 Homo sapiens 35-39 33342939-3 2022 Anagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was shown to decrease LDL cholesterol (LDL-C) levels to a greater extent than that by sitagliptin, another DPP-4 inhibitor, in the Randomized Evaluation of Anagliptin versus Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial. Cholesterol 82-93 dipeptidyl peptidase 4 Homo sapiens 38-43 31990936-2 2020 Several incretin-based drugs are reported to improve lipid metabolism, and one of these medications, anagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that has been shown to decrease serum triglyceride and low-density lipoproteins cholesterol. Cholesterol 239-250 dipeptidyl peptidase 4 Homo sapiens 118-140 31990936-2 2020 Several incretin-based drugs are reported to improve lipid metabolism, and one of these medications, anagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that has been shown to decrease serum triglyceride and low-density lipoproteins cholesterol. Cholesterol 239-250 dipeptidyl peptidase 4 Homo sapiens 142-147 33737166-0 2021 Expectations for synergistically favorable effects of the combination therapy with DPP-4 inhibitor and SGLT2 inhibitor on cholesterol synthesis and absorption. Cholesterol 122-133 dipeptidyl peptidase 4 Homo sapiens 83-88 31089516-8 2017 Results: Serum DPP-4 concentration was positively correlated with lean body mass, total cholesterol level, and creatinine level. Cholesterol 88-99 dipeptidyl peptidase 4 Homo sapiens 15-20 31733647-1 2019 BACKGROUND: Anagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). Cholesterol 119-130 dipeptidyl peptidase 4 Homo sapiens 26-48 30674032-8 2019 DPP-4 inhibitors increase fatty oxidation, and cholesterol efflux, and decrease hepatic triglyceride synthase and de novo lipogenesis. Cholesterol 47-58 dipeptidyl peptidase 4 Homo sapiens 0-5 31595792-5 2022 APLN mRNA expression was positively correlated with total and LDL cholesterol plasma level, and DPP4 mRNA expression - with VLDL cholesterol concentration. Cholesterol 129-140 dipeptidyl peptidase 4 Homo sapiens 96-100 30738832-7 2019 Obese patients with body mass index (BMI) >= 30 had a higher level of monocyte DPP4 expression, in parallel with higher levels of HOMA-IR, blood glucose, triglycerides, and non-HDL cholesterol, compared to those in the non-obese (BMI < 30) patients. Cholesterol 184-195 dipeptidyl peptidase 4 Homo sapiens 82-86 30302966-5 2019 Univariate analyses revealed significant correlations of soluble DPP-4 levels with the total cholesterol (r=0.214, P=0.019) and serum creatinine levels (r=-0.315, P<0.001) and the estimated glomerular filtration rate (eGFR; estimated using the modification of diet in renal disease equation) (r=0.303, P=0.001). Cholesterol 93-104 dipeptidyl peptidase 4 Homo sapiens 65-70 28403877-7 2017 From baseline to 24 weeks, HDL-cholesterol (HDL-C) levels were increased by 0.5 (95% CI, -0.9 to 2.0) mg/dl with a DPP-4 inhibitor and by 5.1 (95% CI, 3.0 to 7.1) mg/dl with an SGLT2 inhibitor (p = 0.001). Cholesterol 31-42 dipeptidyl peptidase 4 Homo sapiens 115-120 28403877-8 2017 LDL-cholesterol (LDL-C) levels were reduced by 8.4 (95% CI, -14.0 to -2.8) mg/dl with a DPP-4 inhibitor, but increased by 1.3 (95% CI, -5.1 to 7.6) mg/dl with an SGLT2 inhibitor (p = 0.046). Cholesterol 4-15 dipeptidyl peptidase 4 Homo sapiens 88-93 26474470-10 2015 In normal subjects, sCD26/DPP-IV levels were associated with increased BMI, cholesterol, and LDL-cholesterol (LDL-c) levels. Cholesterol 76-87 dipeptidyl peptidase 4 Homo sapiens 26-32 27006706-5 2016 RESULTS: Following DPP-4 treatment there was a significant reduction in total serum cholesterol (5.18 vs 4.62 mmol/L), low-density lipoprotein (2.89 vs 2.54 mmol/L), hsCRP (3.21 vs 1.95 mg/L), cAiX@75 (24.5 vs 22.3) and central systolic BP (131.8 vs 119.5 mmHg). Cholesterol 84-95 dipeptidyl peptidase 4 Homo sapiens 19-24 26752504-9 2016 Intensification with a DPP4 inhibitor was associated with significant reductions in HbA1c (-0.5%), body weight (-0.9 kg), and total cholesterol (-0.1 mmol/L) (P < 0.001). Cholesterol 132-143 dipeptidyl peptidase 4 Homo sapiens 23-27 27693949-6 2016 Furthermore, DPP-4 activity correlated with waist circumference (r=0.279, p=0.034) and glycated haemoglobin A1c (r=0.483, p<0.001), as well as with LDL cholesterol (r=0.854, p<0.001) and total daily insulin dose (r=0.397, p=0.001). Cholesterol 155-166 dipeptidyl peptidase 4 Homo sapiens 13-18 26603933-6 2015 We hypothesize that GLP-1 mimetics and/or DPP-4 inhibitors modulate ABCA1/ABCG1 expression in adipocytes through an LXR-alpha mediated process and thus affecting cholesterol homeostasis. Cholesterol 162-173 dipeptidyl peptidase 4 Homo sapiens 42-47 26048437-10 2015 DPP-4 inhibitors were associated with a significantly greater decrease in the cholesterol (CHO) level (WMD -0.19 mmol/L; 95 % CI -0.19 to -0.19 mmol/L, p < 0.001) and a significantly greater decrease in the low-density lipoprotein cholesterol (LDL-C) level (WMD -0.16 mmol/L; 95 % CI -0.26 to -0.05 mmol/L, p = 0.003). Cholesterol 78-89 dipeptidyl peptidase 4 Homo sapiens 0-5 26048437-10 2015 DPP-4 inhibitors were associated with a significantly greater decrease in the cholesterol (CHO) level (WMD -0.19 mmol/L; 95 % CI -0.19 to -0.19 mmol/L, p < 0.001) and a significantly greater decrease in the low-density lipoprotein cholesterol (LDL-C) level (WMD -0.16 mmol/L; 95 % CI -0.26 to -0.05 mmol/L, p = 0.003). Cholesterol 91-94 dipeptidyl peptidase 4 Homo sapiens 0-5 26474470-15 2015 In normal subjects, sCD26/DPP-IV levels were associated with increased BMI, cholesterol, and LDL-c. Cholesterol 76-87 dipeptidyl peptidase 4 Homo sapiens 26-32 26259132-8 2015 DPP4 activities were associated positively with triglyceride, total cholesterol, HOMA-IR, IL-6, hs-CRP, C-terminal telopeptide of type I collagen, and osteocalcin and negatively with active GLP-1 and BMD (P < .05). Cholesterol 68-79 dipeptidyl peptidase 4 Homo sapiens 0-4 26259132-7 2015 RESULTS: Participants in the highest quartile of DPP4 activity had higher triglyceride, total cholesterol, HOMA-IR, IL-6, high-sensitivity C-reactive protein (hs-CRP), C-terminal telopeptide of type I collagen, and osteocalcin and lower BMD (lumbar spine and femoral neck) and active GLP-1 compared with participants in the lowest quartile (P < .05). Cholesterol 94-105 dipeptidyl peptidase 4 Homo sapiens 49-53 25110536-1 2014 BACKGROUND: Animal studies have demonstrated that an inhibition of DPP-4 has an impact on the secretion of cholesterol and apoB by the small intestine. Cholesterol 107-118 dipeptidyl peptidase 4 Homo sapiens 67-72 25294850-7 2015 At baseline, individuals in the highest quartile of DPP4 activity had higher age, body mass index, waist/hip ratio, systolic blood pressure, diastolic blood pressure, fasting insulin, low-density lipoprotein-cholesterol, interleukin-6, high-sensitivity C-reactive protein, urinary albumin-to-creatinine ratio and lower high-density lipoprotein-cholesterol compared with individuals in the lowest quartile. Cholesterol 208-219 dipeptidyl peptidase 4 Homo sapiens 52-56 24362783-3 2013 Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogs have been shown to improve glycemic control without promoting weight gain and to exert beneficial effects on lipid profile by reducing total and LDL cholesterol, triglycerides, and free fatty acid levels. Cholesterol 235-246 dipeptidyl peptidase 4 Homo sapiens 0-22 24362783-3 2013 Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogs have been shown to improve glycemic control without promoting weight gain and to exert beneficial effects on lipid profile by reducing total and LDL cholesterol, triglycerides, and free fatty acid levels. Cholesterol 235-246 dipeptidyl peptidase 4 Homo sapiens 24-29 23379505-12 2013 The actual study also revealed an association between the %Meth of this locus with plasma total-cholesterol in severe obesity, which suggests a link between the DPP4 gene and plasma lipid levels. Cholesterol 96-107 dipeptidyl peptidase 4 Homo sapiens 161-165 22923161-9 2012 RESULTS: The difference in mean total cholesterol values at endpoint versus baseline was significantly higher in patients on pioglitazone, sulfonylureas, and DPP-4 inhibitor treatment (but not on acarbose) than those on placebo, demonstrating that treatment with these drugs (except acarbose) is associated with a significant reduction in total cholesterol. Cholesterol 38-49 dipeptidyl peptidase 4 Homo sapiens 158-163 22179204-8 2012 DPP4 expression levels were negatively correlated with HOMA-IR and positively correlated with serum cholesterol levels. Cholesterol 112-123 dipeptidyl peptidase 4 Homo sapiens 0-4 22398368-8 2012 Additionally, suppression of DPP4 expression with siRNA induced elevated protein levels of FDPS and FDFT1, and increased cholesterol biosynthesis in WM-266-4 cells. Cholesterol 121-132 dipeptidyl peptidase 4 Homo sapiens 29-33 22398368-9 2012 Together, the results from the present study revealed, for the first time, that 5-Aza-CdR exerts its cytotoxic effects in leukemia and melanoma cells through epigenetic reactivation of DPP4 gene and the resultant inhibition of cholesterol biosynthesis in these cells. Cholesterol 227-238 dipeptidyl peptidase 4 Homo sapiens 185-189 22215383-10 2012 The difference-in-means for endpoint versus baseline total cholesterol in patients on DPP-4 inhibitors treatment was significantly higher in comparison with controls, meaning that treatment with DPP-4 inhibitors is associated with a significant reduction in total cholesterol (-0.18 [-0.29; -0.06] mmol/L (-7.0 [-11.2; -2.50] mg/dL); P=0.002). Cholesterol 264-275 dipeptidyl peptidase 4 Homo sapiens 195-200 22215383-3 2012 Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to reduce total cholesterol, but results are inconsistent across trials. Cholesterol 77-88 dipeptidyl peptidase 4 Homo sapiens 0-22 22215383-3 2012 Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to reduce total cholesterol, but results are inconsistent across trials. Cholesterol 77-88 dipeptidyl peptidase 4 Homo sapiens 24-29 22215383-10 2012 The difference-in-means for endpoint versus baseline total cholesterol in patients on DPP-4 inhibitors treatment was significantly higher in comparison with controls, meaning that treatment with DPP-4 inhibitors is associated with a significant reduction in total cholesterol (-0.18 [-0.29; -0.06] mmol/L (-7.0 [-11.2; -2.50] mg/dL); P=0.002). Cholesterol 59-70 dipeptidyl peptidase 4 Homo sapiens 86-91 22215383-11 2012 CONCLUSIONS: This meta-analysis suggests a possible beneficial effect of DPP-4 inhibitors on cholesterol, which, although small, could contribute to the reduction of cardiovascular risk. Cholesterol 93-104 dipeptidyl peptidase 4 Homo sapiens 73-78 22215383-10 2012 The difference-in-means for endpoint versus baseline total cholesterol in patients on DPP-4 inhibitors treatment was significantly higher in comparison with controls, meaning that treatment with DPP-4 inhibitors is associated with a significant reduction in total cholesterol (-0.18 [-0.29; -0.06] mmol/L (-7.0 [-11.2; -2.50] mg/dL); P=0.002). Cholesterol 59-70 dipeptidyl peptidase 4 Homo sapiens 195-200 22215383-10 2012 The difference-in-means for endpoint versus baseline total cholesterol in patients on DPP-4 inhibitors treatment was significantly higher in comparison with controls, meaning that treatment with DPP-4 inhibitors is associated with a significant reduction in total cholesterol (-0.18 [-0.29; -0.06] mmol/L (-7.0 [-11.2; -2.50] mg/dL); P=0.002). Cholesterol 264-275 dipeptidyl peptidase 4 Homo sapiens 86-91 22785237-4 2012 In correlation analyses, DPP4 activity displayed strong positive correlations with BMI (p = 5.5 x 10(-5)) and total cholesterol (p = 0.0014), and a negative correlation with the plasma adiponectin concentration (p = 0.013), but not fasting blood glucose. Cholesterol 116-127 dipeptidyl peptidase 4 Homo sapiens 25-29